Marker Therapeutics awarded $2M grant from NIH SBIR program

Marker Therapeutics announced that the Company has been awarded a $2 million grant from the National Institutes of Health, NIH, Small Business Innovation Research, SBIR, program to support the clinical investigation of MT-601 in patients with non-Hodgkin’s lymphoma, NHL, who have relapsed following anti-CD19 chimeric antigen receptor T cell therapy. “We are pleased to receive the SBIR grant from the NIH to support our clinical Phase 1 study in CAR-relapsed patients with non-Hodgkin’s lymphoma,” said Juan Vera, M.D., President and CEO of Marker Therapeutics. “Although anti-CD19 CAR-T cells are rapidly expanding as a treatment option in patients with hematological malignancies, approximately 40-60% of patients will relapse within the first year of therapy with currently no standard of care for patients post CD19-targeting CAR-T cells. The NIH award process is highly competitive, and we believe that the decision the NIH made suggests the potential scientific merit and the capacity of Marker’s APOLLO study to address an unmet medical need.”